[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100331430":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":17,"responsibleParty":32,"collaborators":35,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":17,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":17,"enrollmentInfo":46,"targetDuration":17,"studyType":49,"phases":50,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":17,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":17},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Diclofenac","ACTIVE_COMPARATOR","100 mg Diclofenac rectally prior to the ERCP",[13],"Drug: Diclofenac",{"label":15,"type":16,"description":15,"interventionNames":17},"No prophylaxis","NO_INTERVENTION",null,[19],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":17},"DRUG","Diclofenac rectally given before the ERCP to prevent pancreatitis",[9],[24],{"name":25,"affiliation":5,"role":26},"Gabriel Sandblom, Ass Prof","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":17,"email":31},"CONTACT","+46704158218","gabriel.sandblom@ki.se",{"type":26,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Gabriel Sandblom","Associate Professor, Senior Consultant",[36],{"name":37,"class":6},"Uppsala University","100331430","phase-2-diclofenac-for-prevention-of-post-erc-pancreatitis-100331430",false,"NCT03595150","Diclofenac for Prevention of Post-ERC Pancreatitis","Inclusion Criteria:\n\n* Patients undergoing ERCP\n\nExclusion Criteria:\n\n* Decision to perform ERCP taken intraoperatively\n* Intolerance\u002Fallergy against NSAID\n* Patients taking NSAID daily\n* Severe cardiac fail (ASA\\>4)\n* Kidney failure (GFR\\\u003C30 ml\u002Fmin)\n* Coagulation disorder\n* History of peptic ulcer bleeding\n* History of abdominoperineal resection\n* Pregnancy\n* Patients who do not understand Swedish","ALL","18 Years",{"count":47,"type":48},1000,"ESTIMATED","INTERVENTIONAL",[51,52],"PHASE2","PHASE3","The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.",[55],"Common Bile Duct Diseases",[57,58,9],"Endoscopic Retrograde Cholangiopancreatography","Pancreatitis","NOT_YET_RECRUITING","2025-08-12",{"date":62,"type":63},"2025-08-13","ACTUAL",{"date":65,"type":48},"2026-01-01",{"date":67,"type":48},"2028-12-31",{"name":5,"class":6}]